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Posttranslational modiﬁcationThe proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degra-
dation by inactivating proteasomes' active-sites.MMcells are exquisitely sensitive to Bortezomib – exhibiting a low-
nanomolar IC50 – suggesting thatminimal inhibition of degradation sufﬁces to killMMcells. Instead,we report, a low
Bortezomib concentration, contrary to expectation, achieves severe inhibition of proteasome activity in MM cells:
the degree of inhibition exceeds what one would expect from the small proportion of active-sites that Bortezomib
inhibits. Our data indicate that Bortezomib achieves this severe inhibitionby triggering secondary changes inprotea-
some structure that further inhibit proteasome activity. Comparing MM cells to other, Bortezomib-resistant, cancer
cells shows that the degree of proteasome inhibition is the greatest inMM cells and only there leads to proteasome
stress, providing an explanation for why Bortezomib is effective against MM but not other cancers.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The proteasome inhibitor (PI) Bortezomib is used as a ﬁrst- and
second-line treatment of multiple myeloma (MM) (Anderson et al.,
2011). Proteasomes' (Finley, 2009; Lander et al., 2012) main function
is to degrade ubiquitinated proteins in a controlled manner (Bedford
et al., 2011; Finley, 2009; Glickman and Ciechanover, 2002).
Proteasomes are comprised of a cylindrical core particle (CP) capped
at each end by a regulatory particle (RP) (Lander et al., 2012; He et al.,
2012). The RP captures and denatures ubiquitin-marked protein sub-
strates, and translocates their unfolded polypeptide chains towards pro-
teolytic active-sites in the CP's lumen (Finley, 2009). CP contains three
types of active-sites, each of which comprises a peptide-docking area
and an exposed catalytic threonine. PIs including Bortezomib prevente inhibitors can treat multiple
t few other cancers. It has been
ations so low that only partial
zomib cannot kill most other
expectedly severe inhibition of
anges in these which further
ght’ and achieves unexpectedly
bition. The greatest inhibition
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en).
. This is an open access article underprotein hydrolysis by forming covalent adducts with the catalytic thre-
onines of the active-sites (Groll et al., 2009; Beck et al., 2012). Somepro-
teasome activity is necessary for any cell to live (Heinemeyer et al.,
1997), not just MM cells (Craxton et al., 2012; Suraweera et al., 2012).
Although the Bortezomib concentrations at which cells of different
cancers die differ widely, from low nanomolar to high micromolar IC50
concentrations, cells of the (incurable) B-cellmalignancyMMare exqui-
sitely sensitive (Shabaneh et al., 2013), hence Bortezomib's success in
treatment of MM (Anderson et al., 2011). Intriguingly, Bortezomib at
its low IC50 concentration causes only a small reduction in proteasomes'
ability to degrade proteins (Kisselev et al., 2006; Shabaneh et al., 2013).
The reduction is small because Bortezomib preferentially inhibits the
chymotrypsin-like (CT-Like) active-site, but – at IC50 – does not inhibit
the caspase-like and trypsin-like active-sites (Fig. S2A) (Kisselev et al.,
2006); however, protein substrates can be hydrolysed by any of the
three types of active-sites (Kessler et al., 2001; Kisselev et al., 2006).
Thus, the question arises why minimal inhibition of proteasome func-
tion sufﬁces to induce apoptosis in MM but not in Bortezomib-
insensitive cells. Several explanations have been proposed, including
high proteasome workload in MM cells (Bianchi et al., 2009; Meister
et al., 2007; Shabaneh et al., 2013).
We report that, surprisingly, a (low) IC50 Bortezomib challenge –
which in-vitro minimally inhibits proteasomes – in living MM cells se-
verely inhibits proteasomes' hydrolytic activity. Our data suggest that,
in living MM cells, a Bortezomib-induced structural change in thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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proteasome inhibition.2. Experimental procedures
Antibodies from Enzo Life Sciences: α-ubiquitin (FK2, PW8810), α-
cleaved caspase 3 (PAb, ADI-AAS-103), α-20S α7 (MoAb LN43, BML-
PW8110), α-Rpn12/S14 (PAb, BML-PW8815), α-Rpn10/S5a (MoAb
S5a-18, BML-PW9250), α-Rpt5/S6a (MoAb TBP1-19, PW8770), α-
Rpt4/S10b (MoAb p42-23, PW8830), α-Rpt2/S4 (PAb, BML-PW8305),
and α-β5i/LMP7 (PAb, PW8355). Antibodies from other sources:
α-streptag (Qiagen, MoAb 34850), α-PARP (CellSignalling, PAb,
#9542) and α-procaspase3 (CellSignalling, PAb, #9661). CTAB-PAGE as
described (Pitcher et al., 2014; Simpson, 2010). Additional Reagents:
Ada-K(Biotin)-Ahx3-L3-VS, epoxomicin (Enzo LifeSciences), Bortezomib
(Millennium/Takeda), Streptactin resin (Qiagen, 30004), Ni++NTA
resin (Sigma-Aldrich, His Select HF Nickel Afﬁnity Gel, H0537 (Fig. 2c),
or His Select agarose, P2266). AnnexinV/7AAD apoptosis staining
(EBioscience 88-8007-74) was used to assess cell viability. Enzymes:
DNase1, micrococcal nuclease, RNaseA/T1, RNaseH, S1 nuclease and
RNAse1 (Fermentas/Thermo), PDE1 from Crotalus adamanteus venom
(Sigma, P3243-1VL). Caspase Inhibitor Set III (Enzo Life Sciences, ALX-
850-227-KI01), used at 1:500 dilution = 4 μM. Antibodies were diluted
in PBS + 0.5% Tween20 for Western blotting, PVDF membranes were
re-probed multiple times (Yeung and Stanley, 2009). Myeloma cell
lines NCI-H929, KMS12-BM, RPMI-8226, OPM2, and the T-lymphocyte
Jurkat cell line, were grown in RPMI (Sigma), supplemented with 10%
v/v FBS, and 1% v/v Pen/strep. Cell fractionation procedure as described
(Pitcher et al., 2014). For fractionation, a cytosol extraction (CE) buffer
(25 mM Tris–HCl [pH 7.8], 5 mM MgCl2/EDTA, 1 mM ATP/ADP, 2 mM
DTT, 150 mM NaCl, 0.1 or 0.5% NP-40/IGEPAL) and nuclear extraction
(NE) buffer (Bakondi et al., 2011) (20 mM HEPES [pH 7.4], 420 mM
NaCl, 0.5mMEDTA, 0.5mMEGTA, 1mMDTT, 1 tablet of inhibitor cock-
tail (Roche, 11-873-580-001) per 50ml)were used.When using the NE
for subsequent afﬁnity-puriﬁcation, 2 volumes of H2O were added to 1
volume NE to reduce the NaCl concentration to physiological levels. For
non-fractionated lysate, cell pellets snap-frozen in LN and stored at
−80 °C were resuspended and combined in 10× volume of CE buffer
and passed through a NanoDeBEE (BEE international) homogeniser at
19,000 PSI. Proteasome activity was measured basically as described
(Kisselev and Goldberg, 2005; Vilchez et al., 2012), using ﬂuorogenic
proteasome substrates Suc-LLVY-AMC, Ac-RLR-AMC, Ac-GPLD-AMC
(Enzo Life Sciences) for the three types of active-site. Cells were lysed
in proteasome activity assay buffer (50mMTris–HCl, pH 7.5, 250mM su-
crose, 5 mMMgCl2, 0.5 mM EDTA, 2 mMATP and 1mMDTT) by passing
cells through a 29 G needle ten times. Fluorescence (380 nm excitation,
460 nm emission) wasmonitored continuously on amicroplate ﬂuorom-
eter for 1 h at 37 °C. Tomeasure for the presence of free 20S proteasomes,
0.015% SDS was added to the proteasome activity assay buffer (Fig. S2C).
For each well, a second was set up with the addition of 40 mM
Bortezomib; any activity in the Bortezomib wells was subtracted from
corresponding wells to compensate for unspeciﬁc protease activity. The
ubiquitinated substrate (G3P) (Matyskiela et al., 2013) was kindly pro-
vided by DrAndreasMartin, and used as described. In-vitro degradation
with puriﬁed yeast (Fig. S4) and human (Fig. 3C,D) proteasomes was
done in PBS supplemented with 2.5 mM ATP, 2.5 mM MgCl2, 2.5 mM
DTT, and 10% DMSO in a total volume of 20 μl. Reaction was performed
for 1 h either at 30 °C or 37 °C (Fig. 3C,D), after which the reaction was
stopped by addition of 20 μl 2× SDS sample buffer and boiled.
Graphs were produced using Graph pad Prism 6. Data plotted were
mean of replicates, with error bars plotted of the standard error of
mean (SEM).
Researchwas supported by Leukaemia LymphomaResearchUK (LLR
Grant10016 to MFK, LLR Gordon Piller Studentship award Grant11043
to MFK, AK, DP), by an MRC-Imperial Conﬁdence-in-Concept (ICiC)grant to MFK, and by the NIHR Biomedical Research Centre at Imperial
College NHS Trust, London.
3. Results
NCI-H929 MM cells were challenged with a lethal (10 nM)
Bortezomib concentration for varying lengths of time. Cells were then
lysed and an artiﬁcial ﬂuorogenic peptide substrate was used to mea-
sure proteasomes' hydrolytic activity (Fig. 1a). Over 0–6/8 h, CT-like
activity declined continually to almost nothing. Onlywhen it was nearly
absent (b10%), after 6–8 hour incubation, was an increase in ubiquitin
conjugate levels observed; intracellular accumulation of ubiquitinated
proteins indicates that proteolyticworkload exceeds proteasome capac-
ity, accumulation being a phenotype which integrates other regulatory
mechanisms in the cell including deubiquitinating enzyme activity
(Fig. 1a; see also Fig. S1A). However, when cells were ﬁrst lysed and
then challenged with 10 nM Bortezomib, only a 40% reduction in
proteasomal (CT-like) activity was observed (Fig. S2A: 61.5% CT-like
activity left, and as previously reported (Kisselev et al., 2006)). A much
stronger-than-expected in-vivo inhibitory effect was also observed for
the other types of proteasomal active-sites (Figs. S2E;S2C).
Predictable explanations for Bortezomib's severe inhibition of
proteasomes' activity in MM cells did not apply: (1) severe inhibition
was not due to prolonged incubation, because exposing puriﬁed
proteasomes in the test tube to 10 nM Bortezomib for longer periods
of time still showed modest inhibition in line with Fig. S2A (Figs. 1B;
Fig. S1B) (Bianchi et al., 2009; Kisselev et al., 2006; Shabaneh et al.,
2013). Furthermore, we identiﬁed a MM cell line, RPMI-8226, in which
CT-like proteasome activity dropped very rapidly, within 2 h, to b10%
(Fig. 1e); this time-frame approaches that of the in-vitro test using cell
lysate (Fig. S2A), but in-vitro 61.5% of activity remains. (2) Although
10 nMBortezomib induced apoptosis, and apoptosis is known to inhibit
proteasomes via caspase activation (Sun et al., 2004; Adrain et al., 2004),
caspase activation was not responsible for the observed proteasome in-
hibition: inhibition preceded caspase activation (Fig. 1c), occurredwhen
caspase inhibitorswere present (Fig. 1d), cellswere alive until 10 h post-
challenge asmeasured by Annexin-V staining (Fig. S2B), and therewas a
non-myeloma, T-lymphocyte cell line that did not die with 10 nM
Bortezomib but in which proteasome activity still dropped well beyond
expectation to ~20% (Figs. 1F,S2D; see also lung carcinoma A549 cells:
Fig. S2D). (3) Severe inhibition was not because MM cells actively
pumped in and/or retained Bortezomib to establish a 10–100 fold higher
(Fig. S2A) intracellular Bortezomib concentration.We used the irrevers-
ible biotinylated inhibitor Ada-K(Biotin)-Ahx3-L3-VS (Kessler et al.,
2001) to simultaneously measure inhibition of activity and the degree
to which active-sites were inhibited, i.e. biotinylated (Kessler et al.,
2001). We observed in-vivo a discrepancy between active-site inhibi-
tion and reduction in hydrolytic activity of those active-sites (Fig. 2a).
We now report a structural change in the proteasome which does
correlatewith Bortezomib-triggered early shutdown of proteasomal ac-
tivity: Bortezomib-triggered early changes in posttranslational modiﬁ-
cations on proteasomal subunits. We recently reported that human
nuclear proteasomes carry a constitutive, CTAB-PAGE-detectable, post-
translational modiﬁcation that, in some respects, resembles poly(ADP)-
ribose (Pitcher et al., 2014). We reported that exposing MM cells to
Bortezomib induced changes in these CTAB-PAGE-detectable protea-
some modiﬁcations, exactly at Bortezomib's IC50 concentration and
above (Pitcher et al., 2014). Fig. 2b – CTAB-PAGE analysis of total cell ly-
sate – shows that changes in these modiﬁcations of the proteasomal
Rpn12 subunit occur between 1 h (RPMI-8226) and 4 h (H929) of PI
challenge. To examine these Bortezomib-triggered changes in ﬁner de-
tail, we combined cell fractionation with afﬁnity-puriﬁcation of human
proteasomes. (Puriﬁcation is a technical trick that enables modiﬁed
subunits to also become compatible with, and visible on, SDS-PAGE
(Pitcher et al., 2014).) We generated retrovirally-transduced OPM2
MM cells, which expressed a Rpn11 subunit tagged N-terminally with
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Fig. 1. Exposing myeloma cells to a lethal Bortezomib concentration leads to much greater inhibition of proteasomal hydrolytic activity in-vivo than is seen with cell lysate or puriﬁed
proteasomes. (a) Measuring over time the effects on CT-like proteasome activity in Bortezomib-sensitive multiple myeloma cells (NCI-H929) after a 10 nM Bortezomib challenge (n = 2
per value). For the same time points, the degree of accumulation of ubiquitin conjugates in NCI-H929 cell lysate is visualised (see also Fig. S1A). Data represented as mean ± SEM.
(b) Measuring the level of inhibition of puriﬁed human 26S proteasomes following pre-incubation with 10 nM Bortezomib from 1 to 5 h at 4 °C (CT-Like activity was measured using
Suc-LLVY-AMC at 37 °C). Data represented as mean ± SEM. Fig. S1B: experiment done also with yeast 26S proteasomes, and with higher pre-incubation temperature. (c) Time course ex-
periment with NCI-H929 cells, looking at caspase 3 activation and PARP cleavage (Substrate of Caspase 3), following a 10 nM Bortezomib challenge. (d) Investigating the effect of caspase
inhibitors on Bortezomib's ability to shut down over time CT-Like activity in NCI-H929 cells. For experimental procedure, and validation that the procedure indeed inhibited caspases, see
(Pitcher et al., 2014). Data represented as mean ± SEM (n = 2 per value). (e) Measuring over time the effects on CT-like proteasome activity in Bortezomib-sensitive multiple myeloma
cells (RPMI-8226) after a DMSO, 1 nM (sub-lethal) and 10 nM (lethal) Bortezomib challenge. Data represented as mean ± SEM (n = 2 per value). (f) Measuring over time the effects on
CT-like proteasome activity in the Bortezomib-insensitive T lymphocyte Jurkat cell line. Annexin-V staining showed that this 10 nM Bortezomib challenge did not induce cell death in the
Jurkat cells. Data represented as mean ± SEM. See also Figs. S1,S2.
644 D.S. Pitcher et al. / EBioMedicine 2 (2015) 642–648a His6–StrepII–StrepII–TEV-afﬁnity cassette. Cell fractionation and then
afﬁnity-puriﬁcation (using streptactin or Ni++NTA) showed that sub-
units from speciﬁcally nuclear proteasomes are extensively modiﬁed,
as we reported previously (Pitcher et al., 2014) (Fig. 2c: Rpn11 subunit,
detected with anti-streptag antibody). Repeating this fractionation-
then-afﬁnity-puriﬁcation procedure, but this time after OPM2 cells
had been treated with 20 nM (lethal) Bortezomib for up to 5–7 h,
showed that patterns of modiﬁed subunits changed (Fig. 2d,e). These
changes' characteristics dependedon the particular proteasome subunit
thatwas analysed. Generalising, these changes involved (A) a reduction
in complexity for nuclear proteasomes (e.g. Rpt5, Rpn12), and/or
(B) the appearance of modiﬁed subunit species in the cytosol fraction(e.g. β5i, Rpn12). (A) and (B) raise the possibility that severe inhibition
of proteasome activity in total lysate (Fig. 1)may result from changes in
proteasome structure which happen both in the cytosolic and nuclear
compartments of the cell after cells are challenged with Bortezomib.
We are currently investigating the exact nature of the proteasome
modiﬁcations.
In order to test directly if changes in these proteasomemodiﬁcations
affect proteasome function, we ﬁrst searched for commercial enzyme
preparations that can digest the modiﬁcations of nuclear proteasomes.
We discovered that a combination of venom phosphodiesterase-1 and
S1 nucleasewas efﬁcient in trimming thesemodiﬁcations and collapsing
modiﬁedRpt2 species into its correct subunit-size species (Fig. 3A). Next,
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the right shows afﬁnity-puriﬁcation of proteasomes from both cytosolic (CE) and subsequent nuclear (NE) extract by Ni++NTA or Streptactin capture. Extraction done as described
(Pitcher et al., 2014), using 0.1% NP40 in CE buffer. Note that themanymodiﬁed nuclear species of Rpn11 cannot be visualised on SDS-PAGE unless puriﬁed, and thus – after puriﬁcation –
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(d) Tagged proteasomeswere afﬁnity-capturedwith Ni++NTA from CE and NE from 7-hour control- (PBS) or Bortezomib-treated (20 nM) Rpn11-tagged OPM2 cells. These proteasomes
were run on SDS-PAGE, and then blotted for various proteasomal subunits. Extraction done as described (Pitcher et al., 2014), but CE buffer contained 0.5% NP40. (e) Same as in (d), but
cells were harvested – and proteasomes were captured – after only 5 h of incubation with Bortezomib. See also Fig. S3.
645D.S. Pitcher et al. / EBioMedicine 2 (2015) 642–648we combined this enzyme protocol with an in-vitro proteasome-
mediated proteolysis assay, which uses a ubiquitinated model protein
as substrate (Matyskiela et al., 2013) (Figs. 3B, S4). We scaled up cell
growth and afﬁnity-puriﬁed proteasomes from total (i.e. includingnuclear) lysate. Proteasomes bound to afﬁnity-resin were mock-treated
or treated with PDE1/S1 at a sub-optimal (20 °C) temperature, after
which resin was washed to remove enzymes. Next, proteasomes were
eluted to generate a control and a PDE1/S1-treated proteasome
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646 D.S. Pitcher et al. / EBioMedicine 2 (2015) 642–648preparation. Most subunits of PDE1/S1-treated versus untreated
proteasomes were very similar, but for example Rpn12 showed pro-
nounced differences (Fig. S3). We then incubated the proteasome prepa-
rations with a ubiquitinated model protein (Matyskiela et al., 2013)
(Fig. S4) in order to assess the ability of these proteasome preparations
to process a ubiquitinated substrate. At low proteasome/substrate ratio
at 30 °C, the PDE1/S1-treated proteasomes were impaired in degrading
ubiquitinated substrate (Fig. 3C). However, increasing the ratio overcame
this defect, with both preparations degrading substrate equivalently. Ateven higher proteasome/substrate ratio, and at 37 °C, proteasomes proc-
essed the substrate towards deubiquitination rather than degradation,
and again both preparations behaved equivalently (Fig. 3B). In addition,
we found that changes in the redox state of the reaction conditions un-
covered qualitative differences between enzyme-treated and untreated
proteasomes (Fig. 3D): in the oxidizing conditionsminus DTT, enzyme-
treated proteasomes removed streptag epitope (i.e. substrate) more ef-
ﬁciently than untreated proteasomes but did not shift down the ubiqui-
tin signal correspondingly, indicating that these enzyme-treated
647D.S. Pitcher et al. / EBioMedicine 2 (2015) 642–648proteasomes only partially digested the substrate protein – starting
from the tagged carboxyterminus – before premature release. In con-
trast, under reducing conditions, untreated proteasomes were more ef-
ﬁcient in degrading substrate than enzyme-treated proteasomes (see
also Fig. 3C). In sum, our data indicate that, under certain experimental
conditions, changes in proteasome modiﬁcations affect proteasome
function, thereby strengthening the case that Bortezomib-triggered
changes in proteasome modiﬁcations within cells also affect protea-
some function.4. Discussion
In summary, our data reveal a dramatic inhibition of proteasome
activity inMMcells after a (low) IC50 Bortezomib challenge, and suggest
that this inhibition is the compound result of, ﬁrst, inhibition of a subset
of active-sites, and, second, structural changes in the proteasomewhich
further impair hydrolytic activity (Fig. 3E). Engagement of PIs with
active-sites changes proteasome conformation and stabilizes the
(distant) CP–RP (Kleijnen et al., 2007; Park et al., 2008) and RP-hPLIC/
ubiquilin (Kleijnen et al., 2000) interactions, thus providing a possible
signalling mechanism into the cell that may enable active-site inhibi-
tion to directly trigger activation of the cellular machinery that then
changes the posttranslational modiﬁcations of the proteasomes.
Whereas it has been very difﬁcult to explain why MM cells die from a
nanomolar IC50 Bortezomib challenge when assuming that the modest
level of proteasome inhibition observed in-vitro holds true in-vivo
(Bianchi et al., 2009; Kisselev et al., 2006; Shabaneh et al., 2013), it is
not surprising that a myeloma cell with over 95% CT-inhibition and ob-
servable proteasome stress (i.e. accumulation of ubiquitin conjugates,
Fig. 1a) will undergo apoptosis. In addition, our data show that
Bortezomib, in cancer cells which are Bortezomib-resistant, does not
achieve the same degree of proteasome inhibition as in (Bortezomib-
sensitive) MM cells (Figs. 1F, S2D), thus providing a molecular mecha-
nism explaining what differentiates MM from most other cancers
which Bortezomib cannot treat. Please note that our data indicate that
a high proteasome workload in MM cells (Bianchi et al., 2009; Meister
et al., 2007; Shabaneh et al., 2013) cannot be the primary reason for
MM cells' sensitivity to Bortezomib: for this explanation to work, all
proteasomes in a cellwould need to be fully engaged –withno spare ca-
pacity left – in order for aminimal inhibition of proteasomes to produce
proteasome stress; instead, we observed that MM cells have much
spare proteasome capacity, and that reducing capacity even to 20%
still did not yield proteasome stress (Fig. 1a). Understanding the cellular
mechanism via which Bortezomib ampliﬁes its effect on proteasome
function may enable future intervention to re-sensitize Bortezomib-
resistant cells to treatment.Authorship contributions
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